Leo Pharma, a multinational Danish manufacturer of pharmaceuticals, has announced the company will cut 300 jobs from it's Danish workforce. The restructuring is a result of the closure of their Ballerup research department which had 300 workers, including researchers, support and distribution staff. The closure of the research department is part of the company's new strategy, outsourcing innovation and research externally. Further, the future strategy for the company is to manufacture pharmaceuticals on license from other biotek companies. 

Leo Pharma has a presence in more than 100 countries and employs around 1700 people in Denmark.

A previous restructuring event was recorded in the ERM Events database for Leo Pharma. In 2022, the company announced a global restructuring which will impact 1000 employees from 2022-2024 (Leo Pharma-2022-WO).